TICKERNERD
Menu
ELVELVHealthcare · Healthcare Plans

ELV Stock Forecast: Elevance Health, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$408
−1.76% on the day

The 22 Wall Street analysts covering Elevance Health, Inc. hold a median 12-month price target of $457 — +12.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 5 Sept 2026 — in the upper half.

Market cap
$88.4B
Ticker Nerd rank
68 / 100
Median analyst target
$457
Analysts covering
22
Revenue$50.5B+1.4% y/y
Net income$1.5B
Free cash flow$1.6B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.3%
1M
+7.8%
YTD
+17.4%
1Y
+35.0%
From 52W high
−4.5%
From 52W low
+46.6%
$278
$427
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elevance Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
89
Volatility
89
Momentum
80
Issuance
74
Revisions
73
Growth
53
Quality
38
Accruals
38
Size
3

Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$350$400$450$500Oct 25Jan 26Apr 26Jul 26ELVHigh $492Median $457Low $393

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
15 Buy7 Hold0 Sell
Low $393Median $457High $492

The green dot is the last close — the median target sits +12.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 July 2026Leerink PartnersMaintainsMarket Perform$364 → $395
16 July 2026BairdMaintainsNeutral$331 → $393
16 July 2026BarclaysMaintainsOverweight$480 → $457
16 July 2026GuggenheimMaintainsBuy$399 → $455
16 July 2026RBC CapitalMaintainsSector Perform$439 → $424
16 July 2026Wells FargoMaintainsOverweight$492 → $473
14 July 2026TD CowenMaintainsBuy$400 → $465
14 July 2026Truist SecuritiesMaintainsBuy$450 → $475
13 July 2026Wells FargoMaintainsOverweight$391 → $492
9 July 2026RBC CapitalMaintainsSector Perform—
9 July 2026RBC CapitalMaintainsSector Perform$358 → $439
7 July 2026Cantor FitzgeraldMaintainsOverweight$400 → $450
7 July 2026Cantor FitzgeraldMaintainsOverweight—
2 July 2026BernsteinMaintainsOutperform—
8 June 2026JP MorganMaintainsOverweight—
8 June 2026MizuhoMaintainsOutperform—
4 June 2026B of A SecuritiesMaintainsBuy—
4 June 2026Morgan StanleyMaintainsEqual-Weight—
1 June 2026Truist SecuritiesMaintainsBuy—
26 May 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Elevance Health, Inc. returned +35.0% against +20.0% for the S&P 500, dividends included.

ELV vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Oct 25Jan 26Apr 26Jul 26ELVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.9%
Analysts raising
0
Analysts cutting
1
Fundamentals

Elevance Health, Inc. (ELV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.0×

Cheaper than 41% of US stocks

Price / sales
0.4×

Cheaper than 84% of US stocks

Price / book
2.0×

Cheaper than 47% of US stocks

EV / EBITDA
9.9×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
1.4%

Higher than 31% of US stocks

Earnings growth (YoY)
−16.1%

Higher than 23% of US stocks

Gross margin
—
Operating margin
4.6%

Higher than 54% of US stocks

Net margin
2.5%

Higher than 53% of US stocks

Returns & dividend
Return on equity
11.1%

Higher than 66% of US stocks

Return on assets
3.8%

Higher than 70% of US stocks

Dividend yield
1.7%

Higher than 39% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Elevance Health, Inc. (ELV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elevance Health, Inc. has a market value of $88.4B and an enterprise value of $82.0B.

  • Revenue in the twelve months to 30 June 2026: $201.1B. The latest quarter grew 1.4% year on year.

  • Net income over the same four quarters: $4.9B, a 2.5% net margin.

  • Diluted earnings per share, trailing twelve months: $22.50.

  • Free cash flow in the twelve months to 30 June 2026: $6.3B, after $1.2B of capital spending.

  • Elevance Health, Inc. spent $2.7B on share buybacks and $1.5B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 216.8M.

  • Trailing P/E: 18.0×; forward P/E: 13.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.69%, paying out 30% of earnings.

  • Elevance Health, Inc. employs 96,129 people — $2.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

ELV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
ELVElevance Health, Inc.$88.4B
68
CIThe Cigna Group$74.7B
70
CVSCVS Health Corp.$122.8B
88
HUMHumana, Inc.$48.3B
45
CNCCentene Corp.$33.0B
94
UNHUnitedHealth Group, Inc.$359.7B
75
MOHMolina Healthcare, Inc.$10.3B
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elevance Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELV news & analysis

UnitedHealth vs. Elevance: Which Managed-Care Stock Is a Better Buy?

Zacks Investment Research · 25 Aug 2026negative

Zacks Investment Research compares UnitedHealth (UNH) and Elevance Health (ELV), concluding that UNH outpaces ELV with stronger earnings prospects, improving Medicare profitability, greater upside, and a more favorable risk-reward profile. The analysis positions Elevance as the weaker of the two managed-care stocks.

Why it matters — Elevance watchers would care because the comparison highlights perceived weaknesses in ELV's earnings outlook and Medicare profitability relative to a key competitor.

Elevance Health (ELV) Up 6.8% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 14 Aug 2026neutral

Elevance Health (ELV) reported earnings 30 days ago, and its stock has risen 6.8% since that report. The article questions whether the stock can continue its upward momentum.

Why it matters — Investors watching ELV would care about whether the post-earnings stock gain signals continued growth or a peak in the share price.

Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey

Business Wire · 30 July 2026positive

Elevance Health announced enhancements to its connected cancer care model, aimed at providing earlier support, personalized care navigation, and more coordinated care for consumers throughout their cancer journeys.

Why it matters — This initiative could strengthen Elevance's value proposition in the healthcare market by addressing a significant, emotionally and logistically complex area of patient care.

Oakmark U.S. Large Value Strategy Q2 2026 Portfolio Review

Seeking Alpha · 29 July 2026neutral

The Oakmark U.S. Large Value Strategy's Q2 2026 portfolio review discusses Delta Air Lines as a contributor despite fuel price headwinds from the Iran War, a decline in Intercontinental Exchange stock price due to AI disruption concerns, and a new position in Equitable Holdings. No mention of Elevance Health (ELV) appears in the report.

Why it matters — ELV watchers would note that the Oakmark strategy review contains no information directly relevant to Elevance Health, as the discussion focuses on other portfolio holdings.

GreensKeeper Value Fund Q2 2026 Portfolio Update

Seeking Alpha · 27 July 2026neutral

The GreensKeeper Value Fund's Q2 2026 portfolio update does not mention Elevance Health, Inc. The fund noted ICON plc as its top performer and Intercontinental Exchange as its largest detractor, with no major portfolio changes made during the quarter.

Why it matters — ELV watchers would note that the fund's update contains no new information or positioning changes regarding Elevance Health.

FAQ

Frequently asked questions about ELV stock

What is the ELV stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Elevance Health, Inc. have a median 12-month price target of $457, with estimates ranging from $393 to $492. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELV stock a buy right now?

Of the 22 analysts covering Elevance Health, Inc., 15 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elevance Health, Inc. 68 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELV?

As at 5 Sept 2026, Elevance Health, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).

Will ELV stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +12.1% from the last close, and Ticker Nerd's factor model ranks Elevance Health, Inc. 68 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELV stock forecast for 2030?

No analyst covering Elevance Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $393 to $492 over the next 12 months.

How has ELV stock performed over the past year?

Elevance Health, Inc. returned +35.0% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elevance Health, Inc. do?

Elevance Health, Inc. is a U.S.

What is the latest news on ELV?

The most recent item we track (Zacks Investment Research, 25 Aug 2026): "UnitedHealth vs. Elevance: Which Managed-Care Stock Is a Better Buy?". Zacks Investment Research compares UnitedHealth (UNH) and Elevance Health (ELV), concluding that UNH outpaces ELV with stronger earnings prospects, improving Medicare profitability, greater upside, and a more favorable risk-reward profile. The analysis positions Elevance as the weaker of the two managed-care stocks.

Company

About Elevance Health, Inc.

Elevance Health, Inc. is a U.S. health benefits and health services company headquartered in Indianapolis, Indiana. It provides a broad range of health insurance products and related services for individuals, employers, and government-sponsored programs, with offerings that include commercial medical coverage, Medicare and Medicaid plans, dental, vision, behavioral health, and pharmacy benefits. The company operates through Health Benefits, CarelonRx, Carelon Services, and Corporate & Other, combining insurance operations with care management and healthcare enablement services. Elevance Health serves as a major participant in managed care, helping coordinate medical coverage, administrative services, and integrated care solutions across the U.S. healthcare system. Its portfolio is designed to support members, providers, and employer groups through a whole-health approach that links benefits, clinical support, and pharmacy services.

CEO Ms. Gail Koziara Boudreaux · 96,129 employees · United States · https://www.elevancehealth.com